Streetbeat News

TSHA

Taysha Gene Therapies, Inc.

https://www.tayshagtx.com

Industry

Biotechnology

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Open

2.22

Mkt cap

434M

Volume

5.6M

High

2.28

P/E Ratio

3.37

52-wk high

4.32

Low

2.06

Div yield

N/A

52-wk low

1.19

Over the past three months, 16 analysts have shared their insights on Taysha Gene Therapies (NASDAQ:TSHA), with opinions ranging from bullish to bearish. The average 12-month price target has increased by 20.07% to $7.06. Analysts have maintained or raised their ratings, with notable actions including Jefferies raising its price target from $2.00 to $8.00.

Portfolio Pulse from Benzinga Insights

June 17, 2024 | 3:00 pm

Needham analyst Gil Blum has reiterated a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 10:00 am

Taysha Gene Therapies announced it will host a webcast on June 18, 2024, to present clinical data from its Reveal Phase 1/2 trials.

Portfolio Pulse from Benzinga Newsdesk

June 12, 2024 | 11:03 am

16 analysts have shared their evaluations of Taysha Gene Therapies (NASDAQ:TSHA) over the past three months, showing a mix of bullish and somewhat bullish perspectives. The average 12-month price target has increased by 46.11% to $6.94. Analysts have maintained or raised their ratings, with the highest price target set at $9.00. Despite financial challenges, including a -27.52% revenue decline and high debt-to-equity ratio, analysts remain optimistic about the company's future.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 3:00 pm

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 1:15 pm

Needham analyst Gil Blum has reiterated a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 10:04 am

Taysha Gene Therapies (NASDAQ:TSHA) reported Q1 EPS of $(0.10), surpassing the $(0.11) estimate, and sales of $3.41M, exceeding the $2.56M estimate. This represents a 64.29% improvement in EPS and a 27.52% decrease in sales year-over-year.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 8:13 pm

Jefferies analyst Eun Yang assumes coverage of Taysha Gene Therapies (TSHA) with a Buy rating and raises the price target to $8.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 12:20 pm

Needham analyst Gil Blum reiterated a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 5:20 pm

Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

April 30, 2024 | 2:27 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.